TGTX

TentativeAI MemoPost-earnings T+3

TG Therapeutics

As of 2026-08-06/Post-earnings T+3/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-06 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

peer set is too generic or lacks enough direct operating comparators; later post-earnings follow-up lacks concrete company-source and analyst/market reaction evidence

Action

—

Confidence

medium

Horizon

—

Key catalyst

Q2 commercial strength and raised BRIUMVI guidance • 2026-08-03

Base target: $55 / p=50% prob

Biggest risk

The investment case remains concentrated in BRIUMVI, while future value depends on sustained uptake, payer and supply execution, clinical development, and regulatory success. The negative deterministic forward prior suggests the market may already discount much of the guidance improvement.

Invalidation

Break below $42 or thesis failure.

What would change my mind?

Q2 commercial execution was strong, guidance was raised, and positive ENHANCE results plus subcutaneous BRIUMVI development extend the product's potential beyond the current regimen. [#SEC-8K-2026-08-03]

Research note

Recommendation

—

Confidence

medium

As of

2026-08-06

Base target

$55

p=50%

Bull target

$70

p=25%

Bear target

$42

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Post-print expectation digestion
Subcutaneous BRIUMVI Phase 3 readout
Azer-cel preliminary data and BRIUMVI expansion studies

BearKey bullets

Azer-cel, MG, and schizophrenia programs remain early-stage and may not generate timely validation.
High dependence on BRIUMVI commercial momentum and the ability to sustain prescriptions, payer coverage, and supply.
Raised guidance may increase expectations, creating downside risk if growth or margins normalize.

WatchKey bullets

Q2 commercial strength and raised BRIUMVI guidance

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Post-earnings T+3

Base case: $55 (p=50%)

Target spread vs base: +27% / -24%

Scenario probabilities

Bull Target: $70 (p=25%)Base Target: $55 (p=50%)Bear Target: $42 (p=25%)

Commentary

The company-source tone is constructive after strong Q2 revenue, raised guidance, positive ENHANCE results, and dated development milestones. However, later post-earnings market reaction and analyst revisions remain thin: the available analyst evidence is pre-print, and no reliable post-print price attribution was verified. Direct MS comparators improve the peer context, but the thesis remains a cautious monitoring view rather than a high-conviction upgrade.

As of 2026-08-06 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Post-print expectation digestion
Subcutaneous BRIUMVI Phase 3 readout
Azer-cel preliminary data and BRIUMVI expansion studies

Scenarios

Bull Target (Scenario probability)

$70 / p=25% prob

Base Target (Scenario probability)

$55 / p=50% prob

Bear Target (Scenario probability)

$42 / p=25% prob

Analysis 2026-08-06 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-08-03
Q2 commercial strength and raised BRIUMVI guidance
Q2 2026 total global revenue was approximately $240.3 million, including $227.7 million of BRIUMVI U.S. net product revenue, up approximately 64% year over year. TG Therapeutics raised its full-year 2026 global revenue target to approximately $950 million and BRIUMVI U.S. revenue target to approximately $890-$905 million. [#SEC-8K-2026-08-03]
Prob 95.00% • Move 4.00% • Priced-in 85.00%

Short-term Catalysts

Next few weeks

Post-print expectation digestion
2026-11-04
The deterministic post-earnings prior turned negative despite strong reported results, indicating elevated expectations and possible near-term profit-taking. No reliable post-print price attribution or analyst revision tape was verified, so this remains a risk rather than confirmed market reaction.
Prob 60% • Move -3% • Priced-in 65%

Long-term Catalysts

Months to a year

Subcutaneous BRIUMVI Phase 3 readout
2027-08-06
Phase 1 data supported a quarterly subcutaneous dosing regimen, and the fully enrolled Phase 3 trial is expected to produce top-line data at year-end 2026 or in the first quarter of 2027. Success could improve administration convenience and adoption, but regulatory and commercial outcomes remain uncertain. [#SEC-8K-2026-08-03]
Prob 60% • Move 8% • Priced-in 35%
Azer-cel preliminary data and BRIUMVI expansion studies
2027-08-06
TG Therapeutics expects to present preliminary Phase 1 azer-cel data in progressive MS in the second half of 2026 and has initiated Phase 2 studies of BRIUMVI in myasthenia gravis and treatment-resistant schizophrenia. These programs add optionality but remain early-stage. [#SEC-8K-2026-08-03]
Prob 45% • Move 7% • Priced-in 20%

Risks

Azer-cel, MG, and schizophrenia programs remain early-stage and may not generate timely validation.
High dependence on BRIUMVI commercial momentum and the ability to sustain prescriptions, payer coverage, and supply.
Raised guidance may increase expectations, creating downside risk if growth or margins normalize.
Subcutaneous BRIUMVI and ENHANCE follow-through remain subject to clinical, regulatory, labeling, and commercial-acceptance risk.
The post-print EPS surprise, price reaction, and analyst estimate or target revisions remain unverified; pre-print estimates had already been reduced by at least one analyst.

Peers

Symbol	Summary
NVS	Novartis' Kesimpta is an approved subcutaneous CD20 therapy for relapsing multiple sclerosis, making it a close convenience and competitive comparator to subcutaneous BRIUMVI. [Novartis Kesimpta prescribing information](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf)
GILD	Large-cap commercial biopharma benchmark with a broader revenue base and more diversified product mix; useful for comparing execution quality, though TGTX is more concentrated and event-sensitive.
AMGN	Large-cap commercial biotech comparator that highlights the scale, cash-generation, and pipeline-depth premium relative to TGTX's narrower BRIUMVI-led growth story.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-06

Loading AI feed…

Symbol

Summary

NVS

Novartis' Kesimpta is an approved subcutaneous CD20 therapy for relapsing multiple sclerosis, making it a close convenience and competitive comparator to subcutaneous BRIUMVI. [Novartis Kesimpta prescribing information](https://www.novartis.com/us-en/sites/novartis_us/files/kesimpta.pdf)

GILD

Large-cap commercial biopharma benchmark with a broader revenue base and more diversified product mix; useful for comparing execution quality, though TGTX is more concentrated and event-sensitive.

AMGN

Large-cap commercial biotech comparator that highlights the scale, cash-generation, and pipeline-depth premium relative to TGTX's narrower BRIUMVI-led growth story.